A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2014
At a glance
- Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 10 Dec 2012 Planned End Date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 20 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 23 Feb 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.